Press Releases

 
Press Releases
  Date Title and Summary View
Apr 8, 2015
REDWOOD CITY, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that results from retrospective analyses of a large medical database assessing the use of renin-angiotensin-aldosterone-system inhibitor (RAASi) therapy in patients with chronic kidney disease (CKD) and/or heart failure (...
Apr 6, 2015
REDWOOD CITY, Calif., April 6, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on April 1, 2015, the compensation committee of the company's board of directors granted five new employees options to purchase an aggregate of 54,000 shares of the company's common stock with a per share exercise p...
Mar 26, 2015
REDWOOD CITY, Calif., March 26, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that data from a Phase 3 clinical program showing that Patiromer for Oral Suspension (Patiromer FOS), the Company's lead product candidate, was effective in reducing potassium levels and preventing a recurrence of hyperk...
Mar 18, 2015
REDWOOD CITY, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on March 2, 2015, the compensation committee of the company's board of directors granted three new employees options to purchase an aggregate of 24,000 shares of the company's common stock with a per share exercise...
Mar 16, 2015
REDWOOD CITY, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today highlighted multiple data presentations of Patiromer for Oral Suspension (FOS) at the 2015 World Congress of Nephrology. Patiromer FOS, Relypsa's lead product candidate, is an oral potassium binder being developed for the treatmen...
Mar 14, 2015
Sub-group Analysis of AMETHYST-DN Trial Results Led by Bertram Pitt, M.D. Sponsored Panel at ACC Led by Prominent Thought Leader, Dr. Ileana L. Piña, will Review the Latest Data in Management of Hyperkalemia REDWOOD CITY, Calif., March 14, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today a...
Mar 11, 2015
REDWOOD CITY, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2014. Cash, cash equivalents and short-term investments totaled $135.8 million at December 31, 2014, compared to $94.8 million at December 31, 2013...
Mar 4, 2015
REDWOOD CITY, Calif., March 4, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on March 2, 2015, the compensation committee of the company's board of directors granted two new employees options to purchase an aggregate of 9,200 shares of the company's common stock with a per share exercise pri...
Mar 3, 2015
REDWOOD CITY, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the closing of its public offering of 4,485,000 shares of its common stock at a price to the public of $38.50 per share for gross proceeds of approximately $172.3 million, which includes the exercise in full by the under...
Mar 2, 2015
REDWOOD CITY, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that Kristine M. Ball, senior vice president and chief financial officer, will present at the 27th Annual ROTH Conference on March 10, 2015 at 9:30 a.m. PT. To access the live webcasts and subsequent archived recordings of these presentation...
Page:
1
... NextLast
= add release to Briefcase